This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals.
OVERVIEW OF ACTIVITY
Cancers of the genitourinary system affect hundreds of thousands of individuals within the United States each year, accounting for almost 30% of all newly diagnosed human cancer cases. Tumors of the prostate are definitively the most prevalent and are therefore the topic of extensive ongoing clinical research. Consequently, the clinical management of prostate cancer (PC) is frequently in a state of evolution, necessitating rapid and consistent clinician access to emerging data sets of relevance to the continuous delivery of quality cross-functional care.
These video proceedings from a CME symposium held during the 2015 Genitourinary Cancers Symposium feature discussions with leading PC investigators regarding actual patient cases and related clinical research findings. By providing information on the latest research developments in the context of expert perspectives, this activity will assist medical and radiation oncologists, urologists and other healthcare professionals with the formulation of state-of-the-art clinical management strategies to facilitate optimal care for patients with PC.
LEARNING OBJECTIVES
- Explore emerging data on the use of cytotoxic therapy in the setting of hormone-sensitive advanced PC, and consider this information when designing initial treatment plans for appropriate individuals.
- Recall existing and emerging research information demonstrating the effects of secondary hormonal interventions on quality and quantity of life for patients with castration-resistant PC, and use this information to guide treatment planning.
- Consider available research data and expert perspectives on the efficacy and safety of radium-223 chloride as monotherapy or in combination with other treatment modalities, and use this information to appropriately integrate this novel radiopharmaceutical into clinical practice.
- Effectively apply evidence-based research findings in the determination of best-practice sequencing of available immunotherapeutic, chemotherapeutic and secondary hormonal agents for patients with metastatic PC.
- Explore the emerging data and active research evaluating novel agents in the setting of PSA-only recurrent or advanced PC, and discuss the biologic basis for their clinical activity.
- Counsel appropriately selected patients with recurrent, asymptomatic and symptomatic metastatic PC about availability of and participation in ongoing clinical trials.
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME credit is no longer available for this issue
CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue
HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component.
CME credit is no longer available for this issue
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a
conflict of interest resolution process:
Emmanuel S Antonarakis, MD
Assistant Professor of Oncology and Urology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Advisory Committee: Dendreon Corporation, Janssen Biotech Inc; Consulting Agreements: Astellas Scientific and Medical Affairs Inc, Dendreon Corporation, Janssen Biotech Inc, Sanofi; Contracted Research: Genentech BioOncology, Novartis Pharmaceuticals Corporation, Sanofi, Takeda Oncology; Grant and Research Support: Aragon Pharmaceuticals, Dendreon Corporation, Exelixis Inc, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals.
Andrew J Armstrong, MD, ScM
Associate Professor of Medicine and Surgery
Associate Director for Clinical Research in Genitourinary Oncology
Duke Cancer Institute
Divisions of Medical Oncology and Urology
Duke University
Durham, North Carolina
Advisory Committee: Bayer HealthCare Pharmaceuticals; Consulting Agreements: Astellas Scientific and Medical Affairs Inc, Bayer HealthCare Pharmaceuticals, Dendreon Corporation, Janssen Biotech Inc, Sanofi; Contracted Research: Astellas Scientific and Medical Affairs Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Dendreon Corporation, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Janssen Biotech Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi; Speakers Bureau: Dendreon Corporation.
Tomasz M Beer, MD
Grover C Bagby Endowed Chair for Prostate Cancer Research
Professor of Medicine, Hematology and Medical Oncology
Deputy Director
OHSU Knight Cancer Institute
Portland, Oregon
Contracted Research: Astellas Scientific and Medical Affairs Inc, Bristol-Myers Squibb Company, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Novartis Pharmaceuticals Corporation.
A Oliver Sartor, MD
Medical Director
Tulane Cancer Center
Laborde Professor of Cancer Research
Professor of Medicine and Urology
Tulane Medical School
New Orleans, Louisiana
Consulting Agreements: Astellas Scientific and Medical Affairs Inc, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Medivation Inc, Sanofi; Contracted Research: Bayer HealthCare Pharmaceuticals, Progenics Pharmaceuticals Inc, Sanofi.
Mary-Ellen Taplin, MD
Associate Professor of Medicine
Dana-Farber Cancer Institute
Lank Center for Genitourinary Oncology
Boston, Massachusetts
Advisory Committee: Bayer HealthCare Pharmaceuticals, Dendreon Corporation, Janssen Biotech Inc, Medivation Inc, Tokai Pharmaceuticals Inc; Research Funding: Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Medivation Inc.
MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from Astellas Scientific and Medical Affairs Inc/Medivation Inc, Bayer HealthCare Pharmaceuticals, Sanofi and Tokai Pharmaceuticals Inc.
Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: July 2015
Expiration date: July 2016